أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - bimatoprost, quantity: 300 microgram/ml - eye drops - excipient ingredients: sodium hydroxide; hydrochloric acid; dibasic sodium phosphate; benzalkonium chloride; citric acid monohydrate; water for injections; sodium chloride - bimtop is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta- blockers.

إسرائيل - الإنجليزية - Ministry of Health

teva israel ltd - bimatoprost - ophthalmic solution - bimatoprost 0.3 mg / 1 ml - bimatoprost - reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

multichem nz limited - bimatoprost 0.3 mg/ml;  ;   - eye drops, solution - 0.3 mg/ml - active: bimatoprost 0.3 mg/ml     excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate heptahydrate hydrochloric acid purified water sodium chloride sodium hydroxide - monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

sandoz inc - bimatoprost (unii: qxs94885mz) (bimatoprost - unii:qxs94885mz) - bimatoprost 0.3 mg in 1 ml - bimatoprost ophthalmic solution, 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. bimatoprost ophthalmic solution is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see adverse reactions (6.2)]. risk summary there are no adequate and well-controlled studies of bimatoprost ophthalmic solution 0.03% administration in pregnant women. there is no increase in the risk of major birth defects or miscarriages based on bimatoprost postmarketing experience. in embryofetal development studies, administration of bimatoprost to pregnant mice and rats during organogenesis, resulted in abortion and early delivery at oral doses at least 33 times (mice) or 94 times (rats) the human exposure following topical ophthalmic administration of bimatoprost 0.03% to the cornea or conjunctival sac bilaterally once daily, based on the area under the curve (auc). these adverse effects were not observed at 2.6 time

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - brinzolamide, quantity: 10 mg/ml - eye drops - excipient ingredients: benzalkonium chloride; disodium edetate; sodium chloride; tyloxapol; mannitol; carbomer 974p; hydrochloric acid; sodium hydroxide; purified water - brinzoquin eye drops 1.0% are indicated to decrease intraocular pressue in: ocular hypertension & open-angle glaucoma.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - brinzolamide, quantity: 10 mg/ml - eye drops - excipient ingredients: benzalkonium chloride; disodium edetate; sodium chloride; tyloxapol; mannitol; carbomer 974p; hydrochloric acid; sodium hydroxide; purified water - azopt 1.0% eye drops are indicated to decrease intraocular pressure in : ocular hypertension; open-angle glaucoma.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - bimatoprost, quantity: 0.1 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; dibasic sodium phosphate heptahydrate; citric acid monohydrate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - lumigan rc is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

apotex nz ltd - bimatoprost 0.3 mg/ml;   - eye drops, solution - 0.3 mg/ml - active: bimatoprost 0.3 mg/ml   excipient: benzalkonium chloride citric acid dibasic sodium phosphate hydrochloric acid sodium chloride sodium hydroxide - apo-bimatoprost is indicated as a monotherapy for the reduction of elevated intraocular pressure (iop) in patients with chronic glaucoma or ocular hypertension; or as adjunctive therapy in patients not adequately controlled on other agents.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops - excipient ingredients: hydrochloric acid; dibasic sodium phosphate heptahydrate; citric acid monohydrate; benzalkonium chloride; water for injections; sodium chloride; sodium hydroxide - for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta- blockers.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops - excipient ingredients: water for injections; hydrochloric acid; benzalkonium chloride; citric acid monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; sodium hydroxide - for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta- blockers.